NDSRI
| Topic | Replies | Views | Activity | |
|---|---|---|---|---|
| Ascend Laboratories LLC. is voluntarily recalling Dabigatran Etcxilate Capsules due to the presence of a NDSRI, N-nitroso-dabigatran, above the established Acceptable Daily Intake (ADI) level |
|
2 | 98 | March 27, 2023 |
| Unofficial/official surrogates for read-across |
|
5 | 289 | March 27, 2023 |
| NDSRIs standards (for confirmatory testing or ames/other tests) |
|
7 | 317 | March 24, 2023 |
| Drawing a line: Where might the cohort of concern end? |
|
1 | 270 | March 21, 2023 |
| Formation of Dialkyl-N-nitrosamines in Aqueous Solution: An Experimental Validation of a Conservative Predictive Model and a Comparison of the Rates of Dialkyl and Trialkylamine Nitrosation |
|
6 | 285 | February 25, 2023 |
| APIC NA Risk Assessment Template |
|
3 | 137 | December 19, 2022 |
| Pfizer Japan to Curb Shipments and Recall Amoxapine over Carcinogen Risks |
|
3 | 164 | November 10, 2022 |